C. Rapezzi
Epidemiology · 2005–2021
A researcher in the Science corpus: 12 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Epidemiology — 13 citations into it
Whom C. Rapezzi trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from C. Rapezzi's perspective
Ordered by how strongly the researchers C. Rapezzi trusts endorse each paper. Same corpus, a different order for every researcher.
- Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. (Journal of the American College of Cardiology)
- Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. (New England Journal of Medicine)
- Multiple imputation using chained equations: Issues and guidance for practice (Statistics in Medicine)
- Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. (Blood)
- Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. (Journal of the American College of Cardiology)
- Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis
- Safety and efficacy of RNAi therapy for transthyretin amyloidosis. (New England Journal of Medicine)
- Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond (Statistics in Medicine)
- Clinical Prediction Models—a Practical Approach to Development, Validation and Updating
- Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis (Circulation)
Their papers
- Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. (2021) — 978 citations
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy (2018) — 2,161 citations
- Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis (2016) — 1,778 citations
- Genotype and Phenotype of Transthyretin Cardiac Amyloidosis in the United States: The Transthyretin Amyloid Outcome Survey (THAOS) (2016) — 663 citations
- Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy (2014) — 917 citations
- [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. (2014) — 1,999 citations
- A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). (2014) — 1,111 citations
- Guideline of transthyretin-related hereditary amyloidosis for clinicians (2013) — 662 citations
- Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types (2009) — 711 citations
- Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. (2007) — 699 citations
- Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. (2007) — 2,841 citations
- Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. (2005) — 892 citations